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OBJECTIVES: In The Collaborative Atorvastatin Diabetes Study
(CARDS), atorvastatin 10mg reduced CHD (36%) and stroke
(48%) in primary CVD prevention patients in the UK with type
2 diabetes compared to placebo. However the transferability of
the clinical and economic beneﬁts for treatment algorithms and
populations beyond the UK are not known. Despite the fact that
relative risk reductions are similar between different populations,
baseline risk varies according to population. This study outlines
an approach to estimate baseline risk in a non-study diabetes
population and calculate cost-effectiveness therein using the trial
treatment effect. METHODS: A Markov model was developed
using the UKPDS risk function to model the incidence of CHD
and stroke assuming “no treatment”. The model allows re-
calibration of risk for non-study diabetes populations by substi-
tuting the UKPDS population, individual, and mean risk factors
with those of the population of interest. The treatment effect is
determined by multiplying estimated incidence rates by the
hazard ratio observed for CHD and stroke in CARDS. Compet-
ing hazards are used to estimate non-CV mortality. Model end-
points include event rates, estimated costs, survival and QALYs
gained associated with atorvastatin 10mg treatment. RESULTS:
Validity was tested by substituting the CARDS trial population
individual and mean risk factors with those from the UKPDS risk
function. The re-calibrated UKPDS risk function resulted in four-
year “no treatment” CHD predicted risk of 6.70% vs. actual risk
of 6.52% (97.4% of predicted value). The corresponding stroke
incidences were 2.37% and 2.48% (104.8% of predicted value).
CONCLUSION: This approach improves the external validity
by using the annual adjustment of baseline risk and maintains
the internal validity by using observed clinical trial treatment
effects. The re-calibrated model accurately predicted the inci-
dence rates observed in the CARDS trial and enhances general-
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OBJECTIVE: For patients that suffered from an acute myocar-
dial infarct (AMI), the 2001 guidelines of the American Heart
Association (AHA) recommend indeﬁnite treatment with 1)
statins; 2) beta-blockers; 3) ace inhibitors or, if not tolerated,
angiotensin-receptor blockers; and 4) aspirin. This study inves-
tigates how the recommendations are followed by patients and
physicians as observed in pharmacy claims. METHODS: Retro-
spective, claims database study performed using data from a
large health insurer in the Mid-Atlantic region. Patients were
selected if they had an initial AMI episode (ICD-9 Code: 410. ¥
1) between January 1, 2002 and August 31, 2004. These patients
were then matched to their pharmacy claims between January 1,
2001 and December 31, 2004. For each patient, adherence is
deﬁned as the proportion of days covered. RESULTS: A total of
1958 patients were identiﬁed. The mean age was 60 years and
58% were male. Overall post-AMI adherence rates with recom-
mended therapy were as follows: 1) statins: 43%; 2) beta-
blockers: 45%; 3) ace-inhibitors or ARB’s: 36%. Requiring at
least 6 months (1 year, 2 years) of follow-up data post discharge,
adherence rates drop to 1) statins: 42% (40%, 35%); and 2)
beta-blockers: 43% (41%, 35%), ace-inhibitors or ARB’s: 35%
(33%, 29%). A total of 13% of patients can be deﬁned as adher-
ent to the AHA recommendations, ﬁlling more than 80% of all
recommended prescriptions, whereas 19% of patients have ﬁlled
zero of the recommended prescriptions. Notably, 12%-15% of
patients were receiving at least one of the drugs even before their
ﬁrst AMI. In this subgroup adherence rates decrease after the
AMI by 1) statins: 20%; and 2) beta-blockers: 22%, ace-
inhibitors or ARB’s: 30%. CONCLUSION: The AHA post-AMI
treatment recommendations are followed only by a minority of
patients. In addition, mean adherence rates drop after the AMI
if the patient was receiving prophylactic therapy.
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